FIELD: biotechnology.
SUBSTANCE: present invention relates to recombinant production of therapeutic fusion proteins that enhance efferocytosis and can be used in medicine in the treatment or prevention of inflammatory disorders or inflammatory organ damage associated with reduced efferocytosis. Disclosed are versions of fused proteins based on an integrin-binding domain, a phosphatidylserine (PS)-binding domain and a solubilising domain, in which a solubilising domain is inserted between the integrin-binding domain and the PS-binding domain.
EFFECT: invention provides production of fused proteins based on structure of naturally occurring bridge proteins, namely MFG-E8, which function to provide binding of PS-presenting dying cells, debris and microparticles with phagocytes and thus provide triggering of efferocytosis, characterized by reduced stickiness and improved solubility, longer exposure time in blood plasma and higher output when expressed in cell expression systems compared to wild-type MFG-E8 protein with SEQ ID NO: 1.
8 cl, 18 dwg, 9 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2019 |
|
RU2728861C1 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2012 |
|
RU2698655C2 |
| FUSED SERPINE POLYPEPTIDES AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2746550C2 |
| POLYPEPTIDES THAT BIND TO THE C5 COMPONENT OR TO SERUM ALBUMIN AND THEIR FUSION PROTEINS | 2018 |
|
RU2794359C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| NUCLEOTIDE SEQUENCE ENCODING FUSED PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN Dll4 AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IgG4 | 2021 |
|
RU2787060C1 |
| ANTIBODIES CONTAINING POLYPEPTIDE INTEGRATED INTO FRAME REGION 3 | 2019 |
|
RU2796254C2 |
| FUSED PROTEINS WITH ALBUMIN-BINDING DOMAINS | 2018 |
|
RU2786444C2 |
| TGFβR2 MOLECULE WITH TRUNCATED EXTRACELLULAR DOMAIN, FUSION PROTEIN OF TGFβR2 MOLECULE WITH TRUNCATED EXTRACELLULAR DOMAIN, AND ANTI-EGFR ANTIBODIES, AND ANTI-TUMOUR USE OF FUSED PROTEIN | 2021 |
|
RU2824199C1 |
| BISPECIFIC ANTIGEN-BINDING PROTEIN EGFR/CD16 | 2019 |
|
RU2792240C2 |
